oxidative stress induced growth inhibitor family member 2Genealiases: C8orf1 · hT41
Q-omics provides the consensus-scored OSGIN2 profile across patient tissues and cancer cell-line models. OSGIN2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OSGIN2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, OSGIN2 RNA expression shows 19,707 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where OSGIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSGIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSGIN2 survival associations across molecular data types. OSGIN2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSGIN2 RNA expression–survival associations across cancer types. High OSGIN2 expression shows unfavorable associations in MESO, UVM, HNSC, LIHC, LUAD and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OSGIN2 RNA expression.
This table summarizes OSGIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OSGIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSGIN2 shows higher tumor expression in HNSC, KIRP, STAD, BLCA, LIHC and KIRC. The HNSC box plot shows higher OSGIN2 RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with OSGIN2 in patient tissues and cancer cell lines. In patient samples, OSGIN2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OSGIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
